NASDAQ · GMAB
Genmab A/S
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
Loading market information…
NASDAQ · DMRA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Damora Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.48. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Damora Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 1, 2024 | -$3.39+8.38% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $55.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
$82.84-$0.36 (-0.43%)
Disc Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.74% below the high.
$40.42+$1.92 (+4.99%)
Hemab Therapeutics Holdings, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 27.07% below the high.
$25.30+$0.33 (+1.32%)
uniQure N.V.’s quoted price sits in the lower half of its reported 52-week range, 63.85% below the high.
$51.45+$0.71 (+1.4%)
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.51% below the high.
$0.95-$0.02 (-2.3%)
Geron Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.93% below the high.
$11.36-$0.25 (-2.15%)
Keros Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.62% below the high.
